STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3416 by analyst upside · 2026-06-27
LFST
LifeStance Health Group, Inc.
Healthcare · Market Cap $4B · P/E 171.3x
ANALYST PRICE TARGET
+2.6%
implied upside to consensus target
Current Price $10.28
Consensus Target $10.55
Bull Target $13.0
Bear Target $9.0
Analysts Covering 10
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
7
Hold
1
Sell
0
52-Week Low $3.74
52-Week High $10.3
YTD Return +47.7%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) 171.3x
Forward P/E 26.2x
EPS (TTM) $0.06
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.5B
Profit Margin 1.6%
52-WEEK RANGE
52-Week Low $3.74
52-Week High $10.3
Current Price $10.28
Bear Target $9.0
Bull Target $13.0
● Now $10.28 ● Target $10.55
TRADING DATA
Avg Volume 4.1M
YTD Return +47.7%
Analyst Count 10
Consensus Buy
Upside to Target +2.6%
Last Updated 2026-06-27

ANALYST SUMMARY

LifeStance Health Group, Inc. (LFST) is currently trading at $10.28 with a Wall Street consensus price target of $10.55, implying potential upside of 2.6% over the next 12 months. 10 analysts currently cover LFST, with a consensus rating of Buy — 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $13.0, while the most cautious has a target of $9.0.

LFST operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 47.7% year-to-date and is currently trading near the upper end of its 52-week range of $3.74 – $10.3.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LFST, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Goldman Sachs ● Initiated
Buy → Neutral 2026-06-05 Building track record
JP Morgan — Reiterated
Neutral → Neutral 2026-05-14 43% win rate (7 calls)
BTIG — Reiterated
Buy → Buy 2026-05-08 38% win rate (8 calls)
Barclays — Reiterated
Overweight → Overweight 2026-03-06 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-02-26 Building track record
UBS — Reiterated
Buy → Buy 2026-02-26 33% win rate (6 calls)
Keybanc — Reiterated
Overweight → Overweight 2026-02-26 Building track record
BTIG — Reiterated
Buy → Buy 2026-02-02 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →